Pharmacodynamics of taxol in human head and neck tumors.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Research

• Publication date

  1996-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8616855
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines

  2004cited by this paper
• The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines

  2004cited by this paper
• Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol

  1995cited by this paper
• Substoichiometric binding of taxol suppresses microtubule dynamics.

  1995cited by this paper
• Clinical applications of the histoculture drug response assay.

  1995cited by this paper
• Potential of the histoculture drug-response assay to contribute to cancer patient survival.

  1995cited by this paper
• Induction of apoptosis by beta-lapachone in human prostate cancer cells.

  1995cited by this paper
• Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.

  1995cited by this paper
• Chemotherapy‐Induced Apoptosis in Epithelial Ovarian Cancers

  1995cited by this paper
• Inactivation of Bcl-2 by phosphorylation.

  1995cited by this paper
• Paclitaxel (Taxol)

  1994cited by this paper
• Apoptosis and cancer chemotherapy.

  1994cited by this paper
• Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma.

  1994cited by this paper
• p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

  1994cited by this paper
• Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin.

  1994cited by this paper
• Apoptotic cell death during treatment of leukemias.

  1994cited by this paper
• Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction of bcl-2 Gene Expression

  1994cited by this paper
• Paclitaxel (Taxol) for the treatment of head and neck cancer.

  1994cited by this paper
• Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response

  1994cited by this paper
• [Drug resistance, oncogenes, and anti-oncogenes in epithelial tumors].

  1994cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper
• Characterization of a human myeloid leukemia cell line highly resistant to taxol.

  1994cited by this paper
• p53 status and the efficacy of cancer therapy in vivo.

  1994cited by this paper
• P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.

  1994cited by this paper
• Apoptosis in cancer therapy: crossing the threshold.

  1994cited by this paper
• Entamoeba histolytica: target cells killed by trophozoites undergo DNA fragmentation which is not blocked by Bcl-2.

  1994cited by this paper
• [Respective roles of the products of the mdr1 and p53 genes in drug resistance of bronchial cancers].

  1994cited by this paper
• Apoptosis and the cell cycle.

  1994cited by this paper
• Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line.

  1994cited by this paper
• Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle

  1994cited by this paper
• Chimiorésistance, oncogènes et anti-oncogènes dans les tumeurs épithéliales

  1994cited by this paper
• New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues.

  1994cited by this paper
• p53 mutations increase resistance to ionizing radiation.

  1993cited by this paper
• Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer.

  1993cited by this paper
• Detection of 5-bromo-2-deoxyuridine (BrdUrd) incorporation with monoclonal anti-BrdUrd antibody after deoxyribonuclease treatment.

  1993cited by this paper
• Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

  1993cited by this paper
• Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.

  1993cited by this paper
• Histocultures of Patient Head and Neck Tumors for Pharmacodynamics Studies

  1993cited by this paper
• p53-mediated cell death: relationship to cell cycle control

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• The bcl-2 oncogene: apoptosis and neoplasia.

  1993cited by this paper
• Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues.

  1993cited by this paper
• In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance.

  1993cited by this paper
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

  1991cited by this paper
• Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity.

  1991cited by this paper
• P-glycoprotein in human sarcoma: evidence for multidrug resistance.

  1987cited by this paper
• In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture.

  1987cited by this paper
• Taxol: mechanisms of action and resistance.

  1986cited by this paper
• A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

  1985cited by this paper
• Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor.

  1981cited by this paper

• Alpha-fetoprotein mediated targeting of polymeric nanoparticles to treat solid tumors.

  2022cites this paper
• Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma

  2019cites this paper
• Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis

  2017cites this paper
• Nanotechnology for cancer therapy

  2016cites this paper
• Taxane resistance in breast cancer: a closed HER2 circuit?

  2012cites this paper
• SOLID TUMORS : A REVIEW Review Article

  2011cites this paper
• Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

  2011cites this paper
• Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.

  2011cites this paper
• Investigation on the interactions of lymphoma cells with paclitaxel by Raman spectroscopy

  2011cites this paper
• Alteration in TWIST expression: possible role in paclitaxel-induced apoptosis in human laryngeal carcinoma Hep-2 cell line.

  2009cites this paper
• CHAPTER 15 – Chemotherapy in Head and Neck Cancer

  2009cites this paper
• Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines.

  2009cites this paper
• Reverse multidrug resistance in laryngeal cancer cells by knockdown MDR1 gene expression.

  2009cites this paper
• Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer

  2008cites this paper
• Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance

  2008cites this paper
• T-1: A Review

  2007cites this paper
• Tumor Priming Enhances Delivery and Efficacy of Nanomedicines

  2007cites this paper
• Chemotherapeutic implants via subcritical CO2 modification.

  2007cites this paper
• Suramin as a chemo- and radio-sensitizer: preclinical translational studies

  2006cites this paper
• Expression of Basic Fibroblast Growth Factor Correlates with Resistance to Paclitaxel in Human Patient Tumors

  2006cites this paper
• Basic fibroblast growth factor as a therapeutic target for chemosensitization in colorectal cancer.

  2006cites this paper
• Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C.

  2005cites this paper
• Molecular pharmacodynamics of chemotherapy: fibroblast growth factor (FGF) inhibitors as chemosensitizers

  2005cites this paper
• Nontoxic Suramin Treatments Enhance Docetaxel Activity in Chemotherapy-Pretreated Non-Small Cell Lung Xenograft Tumors

  2005cites this paper
• Pharmacodynamics of Doxorubicin in Human Bladder Tumors1

  2005cites this paper
• Preparation and characterization of taxane-containing liposomes.

  2005cites this paper
• Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-Pretreated Human Breast Xenograft Tumors

  2004cites this paper
• Cytostatic and Apoptotic Effects of Paclitaxel in Human Ovarian Tumors

  2004cites this paper
• Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.

  2004cites this paper
• Expression of multi-drug resistance genes (mdr1, mrp1, bcrp) in primary oral squamous cell carcinoma.

  2004cites this paper
• Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.

  2004cites this paper
• Drug Delivery and Transport to Solid Tumors

  2003cites this paper
• Biodegradable paclitaxel-loaded PLGA microspheres for regional treatment of peritoneal cancers.

  2003cites this paper
• Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.

  2003cites this paper
• Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies.

  2002cites this paper
• Differential cytostatic effect of sodium salicylate in human colorectal cancers using an individualized histoculture system

  2002cites this paper
• Induction of FGF as a mechanism of acquired anticancer drug resistance

  2002cites this paper
• Cancer chemoresistance: The relationship between p53 and multidrug transporters

  2002cites this paper
• Clinical aspects of drug delivery to tumors.

  2002cites this paper
• Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors

  2001cites this paper
• Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.

  2001cites this paper
• Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.

  2001cites this paper
• Determinants of drug delivery and transport to solid tumors.

  2001cites this paper
• Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.

  2001cites this paper
• Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity

  2001cites this paper
• Mdr1 Transfection Causes Enhanced Apoptosis by Paclitaxel: An Effect Independent of Drug Efflux Function of P-Glycoprotein

  2001cites this paper
• Long-Term Follow-up on an Intensified Treatment Regimen for Advanced Resectable Head and Neck Squamous Cell Carcinomas

  2001cites this paper
• Role of taxoids in head and neck cancer.

  2000cites this paper
• Paclitaxel‐induced cell death

  2000cites this paper
• Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression 1

  2000cites this paper
• Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer

  2000cites this paper
• Deoxyglucose uptake by a head and neck squamous carcinoma: influence of changes in proliferative fraction.

  2000cites this paper
• Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.

  2000cites this paper
• Determinants of Paclitaxel Penetration and Accumulation in Human Solid Tumor 1

  1999cites this paper
• p53 mutation decreased radiosensitivity in rat yolk sac tumor cell lines.

  1999cites this paper
• Determinants of paclitaxel penetration and accumulation in human solid tumor.

  1999cites this paper
• Intensification regimen 2 for advanced head and neck squamous cell carcinomas.

  1999cites this paper
• Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment

  1999cites this paper
• Quelles nouvelles drogues peut-on utiliser dans les associations chimioradiothérapie ?

  1999cites this paper
• Regional heterogeneity and pharmacodynamics in human solid tumor histoculture

  1999cites this paper
• Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.

  1998cites this paper
• Strategies for using cytoprotective agents to improve outcomes associated with cancer chemotherapy

  1998cites this paper
• Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.

  1998influential citation
• Cytostatic and apoptotic effects of paclitaxel in human breast tumors

  1998cites this paper
• Relationship between paclitaxel activity and pathobiology of human solid tumors.

  1998cites this paper
• Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell.

  1998cites this paper
• Cytotoxic effect of paclitaxel (taxol) either alone or in combination with irradiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro.

  1998cites this paper
• Antiproliferative and Cytotoxic Effects of Geldanamycin, Cytochalasin E, Suramin and Thiacetazone in Human Prostate Xenograft Tumor Histocultures

  1998cites this paper
• Proliferation Indices as Molecular Pharmacodynamic Endpoints in Evaluation of Anticancer Drug Effect in Human Solid Tumors

  1998cites this paper
• Pharmacodynamic Evaluation of Mitomycin C Analog BMS-181174 for Potential use in Intravesical Bladder Cancer Therapy

  1997cites this paper
• Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line.

  1997cites this paper
• Pharmacologic effects of paclitaxel in human bladder tumors

  1997cites this paper
• Differential time dependency of antiproliferative and apoptotic effects of taxol in human prostate tumors.

  1997cites this paper
• Review : Pharmacokinetics and pharmacodynamics of the taxanes

  1997cites this paper
• Apoptosis: A New Pharmacodynamic Endpoint

  1997cites this paper
• Differential Time Dependency of and Apoptotic Effects of Taxol in Prostate Tumors Antiproliferative Human

  1997cites this paper
• Pharmacodynamics of doxorubicin in human bladder tumors.

  1996cites this paper
• Differential Effect of Taxol in Rat Primary and Metastatic Prostate Tumors: Site-Dependent Pharmacodynamics

  1996cites this paper